

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
LATEST STUDY OF PENPULIMAB
IN COMBINATION WITH ANLOTINIB FOR 1L ADVANCED
HCC PUBLISHED AT THE 2021 ASCO GI

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the latest study of Penpulimab (product name: Annike (安尼可); research and development code: AK105), a PD-1 monoclonal antibody drug co-developed by the Group and Akeso, Inc., in combination with Anlotinib Hydrochloride (“**Anlotinib**”; product name: FOCUS V), an antitumor drug self-developed by the Group, for first-line (“**1L**”) treatment of advanced hepatocellular carcinoma (“**HCC**”) has been published at the Gastrointestinal Cancers Symposium 2021 (“**2021 ASCO GI**”).

As of November 2020, the confirmed objective response rate (ORR), disease control rate (DCR), the median progression-free survival (“**PFS**”) and 6-month PFS of Penpulimab in combination with low dosage of Anlotinib (8 mg, 2 weeks-on, 1 week-off) for 1L treatment of HCC were 31.0%, 82.8%, 8.8 months and 63.2%, respectively. The median overall survival (“**OS**”) has not been reached and the 6-month OS rate was 93.2%. The incidence Grade 3 or higher treatment-related adverse events (TRAE) and serious adverse events in relation to Penpulimab or Anlotinib were 19.4% and 6.5%, respectively.

According to the study, the combination of Penpulimab and Anlotinib is safe and tolerable, and has demonstrated encouraging anti-tumor activity for 1L treatment of advanced HCC patients. In addition, the results of the study support the exploration of combination of Penpulimab and higher dosage of Anlotinib. The Phase III clinical trial of the combination of Penpulimab and Anlotinib (10 mg, 2 weeks-on, 1 week-off) for 1L treatment of advanced HCC (NCT04344158) is ongoing.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 20 January 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.